Comparative Pharmacology
Head-to-head clinical analysis: CORTALONE versus HALOG E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTALONE versus HALOG E.
CORTALONE vs HALOG-E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response, and regulate metabolism.
HALOG-E (halcinonide) is a corticosteroid that binds to glucocorticoid receptors, inducing the synthesis of lipocortin, which inhibits phospholipase A2, thereby reducing arachidonic acid release and subsequent production of prostaglandins and leukotrienes. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
10-40 mg orally once daily in the morning; for acute exacerbations, up to 60 mg/day divided into 2-4 doses.
Apply a thin film to affected area twice daily. Initial therapy may be occlusive. Max 60 g/week.
None Documented
None Documented
Terminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life 8-14 hours, prolonged in hepatic impairment; clinical effect persists 24-36 hours due to tissue retention.
Primarily renal (60-70% as unchanged drug), with 10-20% biliary/fecal.
Renal (primarily as conjugates, 60-80%), fecal (15-30%), less than 5% unchanged in urine. Biliary excretion contributes to fecal elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid